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Abstract
TREAT is a computerized decision support system aimed at improving empirical antibiotic treatment of inpatients with suspected bacte-
rial infections. It contains a model that balances, for each antibiotic choice (including ‘no antibiotics’), expected beneﬁt and expected
costs. The main beneﬁt afforded by appropriate, empirical, early antibiotic treatment in moderate to severe infections is a better chance
of survival. Each antibiotic drug was consigned three cost components: cost of the drug and administration; cost of side effects; and
costs of future resistance. ‘No treatment’ incurs no costs. The model worked well for decision support. Its analysis showed, yet again,
that for moderate to severe infections, a model that does not include costs of resistance to future patients will always return maximum
antibiotic treatment. Two major moral decisions are hidden in the model: how to take into account the limited life-expectancy and
limited quality of life of old or very sick patients; and how to assign a value for a life-year of a future, unnamed patient vs. the present,
individual patient.
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TREAT is a computerized decision support system aimed at
improving empirical antibiotic treatment of inpatients with
suspected bacterial infections [1]. It has been tested success-
fully in several clinical studies. In a cluster-randomized clinical
trial, in three hospitals in three different countries, it signiﬁ-
cantly increased the percentage of appropriate empirical treat-
ment and shortened the hospital stay, while at the same time
reducing the use of broad-spectrum antibiotics and antibiotic
costs [2]. TREAT prescribed fewer antibiotic regimens and
more prescriptions of ‘no antibiotic treatment’. Mortality was
reduced, but the study was not powered to show a statistical
signiﬁcance for the reduction in mortality. In a retrospective
analysis in a Danish hospital (with very low percentages of
resistance), TREAT prescribed appropriate antibiotics signiﬁ-
cantly more often than the attending physicians; however,
it did so by somewhat increasing the consumption of anti-
biotics, although not of broad-spectrum antibiotics [3].
The TREAT algorithm is composed of two main parts: a
causal probabilistic network, which uses patient data and
data on the local distribution of pathogens and susceptibili-
ties to provide probabilities for the source of infection,
pathogens and their susceptibility to antibiotics; and a model
that balances, for each antibiotic choice (including ‘no antibi-
otics’), expected beneﬁts and expected costs. For this
balancing act, we have built a cost–beneﬁt model, and
the purpose of this article is to describe the model and the
assumptions that it entailed.
Cost-effectiveness vs. Cost–beneﬁt
In cost-effectiveness (or cost–utility) models, the cost is
divided by the counts for the effectiveness measure: for exam-
ple, what is the cost of preventing one death, and what is the
cost of increasing life-expectancy by one quality-adjusted life-
year (QALY)? In cost–beneﬁt models, the costs and beneﬁts
are expressed in the same units, and the mathematical func-
tion is subtraction. Cost-effectiveness (or cost–utility) models
can be compared to relative risk reduction; cost-beneﬁt is
comparable to absolute risk reduction. We chose to use a
cost–beneﬁt model. We wanted to prevent situations in which
very small absolute gains (i.e. in mild infections) in the denomi-
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2010.03330.x
nator will drive choices of costly antibiotics. The difﬁculty
inherent in cost–beneﬁt models is that loss of life or function
has to be expressed in monetary terms. We still thought that,
for decision support, a model that uses absolute gains rather
than relative ones is preferable.
Perspective
To start counting costs and beneﬁts, we had to select the per-
spective: who is counting? The (strict) perspective of the
patient would be of no interest in this case. It is easy to show
that a model that disregards inﬂuence on future resistance,
and thus harm to future patients, will return, in most instances,
maximum antibiotic treatment [4]. In most European countries
(and Israel), the patient does not bear the cost of in-hospital
antibiotic treatment directly. To choose the patient point of
view would be impractical. The main point made here is that a
cost–beneﬁt (or effectiveness) model that regards future resis-
tance and harm to other patients as an externality will return
maximum antibiotic treatment, which is unacceptable to most
clinicians, and, we hope, to the public as well.
The societal point of view would probably be the most
interesting, but is again impractical. What is the societal cost
of wasting antibiotic drugs? Is it the cost of developing new
antibiotic drugs? What assumptions can we make about the
development of new drugs? What do we mean by ‘societal’?
How wide is the community that we should consider: a coun-
try, a continent, or the whole world? The societal perspective
is interesting, but not useful for decision support needs. We
decided to use the perspective of the institution (hospital);
assuming that the main interest of the institution is to
prolong the lives of patients, and improve their quality of life.
Beneﬁts
The main beneﬁt afforded by appropriate, empirical, early
antibiotic treatment in moderate to severe infections is a
better chance of survival. On the basis of our own data, we
used an OR of 1.6 for the association of inappropriate treat-
ment with a fatal outcome [5], in a group of patients with a
fatality rate of about 30%, to calculate a relative risk for a
fatal outcome, and assumed that this relative risk is stable in
severe and less severe infections (thatis, the absolute gain in
a severe infection is larger). A systematic review and meta-
analysis of the 69 prospective studies that examined the
same question returned a similar OR [6].
How should we use this result? In order to translate it
into a beneﬁt, we have to multiply it by years that were
gained, i.e. by the life-expectancy of the patient. For young
adults, this will return a very large beneﬁt. Little beneﬁt (i.e.
no treatment) will be returned for a 92-year-old patient. This
is unacceptable, and differs enormously from the way in
which we practise antibiotic treatment worldwide. An oppo-
site approach would be to assign to each death prevented a
ﬁxed beneﬁt. However, we are quite convinced that some
patients, at the end of their lives, do not beneﬁt from inter-
ventions. For example, institutionalized patients with Alzhei-
mer’s disease did not beneﬁt from antibiotic treatment [7].
No beneﬁt for appropriate empirical antibiotic treatment
could be shown for bacteraemic patients with severe demen-
tia who were bedridden and had pressure sores (M. Chow-
ers and M. Paul, unpublished data). We need to achieve a
balance between the following: the recognition that infection
is an acute event and, once it is overcome, the patients will
return to their life-path, and that age bias should be avoided;
and the recognition that antibiotic treatment is sometimes
futile, and will incur only costs without beneﬁts.
The solution that we have chosen recognizes the futility of
treating patients with a very guarded short-term prognosis
because of underlying disorders, but assigns the same
beneﬁt to all patients with a favourable short-term prognosis.
From a large database on patients with bacteraemia, we
derived a logistic model predicting 1-month mortality [5], and
then used only terms related to underlying conditions to cal-
culate a probability for 1-month mortality not related to infec-
tion. The terms included were malignancy, functional capacity
(bedridden vs. others), congestive heart failure, intratracheal
intubation (prior to infection), neutropenia, chronic renal
failure, dementia, and age. We assigned the same beneﬁt to all
1-month survivors, 5 years of life, this being the mean survival
of patients with bacteraemia [8]. Thus, TREAT calculates the
probability of being alive at 1 month, independently of the
infection, and multiplies it by 5 years. This is the ﬁgure used
to calculate beneﬁt for the appropriate antibiotic treatment.
This is a solution that worked for decision support. The cor-
rect solution from the point of view of health economics can
be debated. A moral deliberation is required to address the
ethics of alternative solutions.
We have assigned a value of €50 000 to a QALY; this is
the average cost of 1 year on haemodialysis in the countries
that participated in the original TREAT project. The correct
value to use can be debated. However, our results did not
change when the value of a life-year was increased by a fac-
tor of 2 or 4, reﬂecting the facts that the net cost–beneﬁt is
driven by the gain in life-years for the present patient and
loss in life-years for future patients, and that the other costs
and gains are of lesser magnitude. Appropriate treatment
was also assigned a gain of three hospital days [5].
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Costs
Each antibiotic drug was consigned three cost components:
cost of the drug and administration; cost of side effects;
and costs of future resistance. ‘No treatment’ incurs no
costs.
Costs of drug and administration include: the cost of the
drug itself for the (average) 2 days of empirical treatment;
the cost of administration (insertion of an intravenous line,
administration of drug, and cost of the line and infusion set);
and laboratory tests for monitoring.
To assign costs to side effects, we had to distinguish side
effects that may cause death and serious morbidity from
side effects that are a minor nuisance, or laboratory abnor-
malities only. To do this, we compiled a list of common
side effects of antibiotic drugs. Each side effect was assigned
to one of the following cost categories: (i) mild to moder-
ate—this does not involve serious morbidity or risk for
mortality (e.g. reversible rise in creatinine, mild rash or
mild diarrhoea), and cost was expressed as additional hospi-
tal days; and (ii) severe—this carries a risk for mortality
and lasting morbidity (e.g. severe nephrotoxicity requiring
acute or chronic haemodialysis, severe diarrhoea (pseudo-
membranous colitis), Stevens–Johnson syndrome, and a
fatality rate was assigned to each side effect. The transla-
tion of the fatality rate to loss of life-years was performed
as for gains (see above). We also assigned loss of quality of
life for long-term morbidity, e.g. chronic haemodialysis and
irreversible vestibular toxicity. The cost was calculated on
the assumption of a mean survival of 5 years after an epi-
sode of severe infection (adjusted for severity of underlying
conditions). Additional hospital days were added for severe
side effects as well. Using techniques of systematic review
and meta-analysis, we searched for and compiled ﬁgures for
the incidence of each side effect per category of severity,
per drug and per day, and their costs in terms of morbidity
and mortality [9]. The side effects that mostly inﬂuenced
costs were diarrhoea caused by Clostridium difﬁcile, especially
its severe forms, and (rare) severe nephrotoxicity and
severe ototoxicity.
Costs of future resistance are obviously the most difﬁcult
to calculate, but are the ones that we believed would drive
the cost–beneﬁt model. The costs of future resistance are
divided into cost to the individual patient and costs to future
patients. To derive an individual cost of resistance, we
derived from our databases [5] the rate of a severe bacterial
infection in the month following another bacterial infection
(0.1%). We then determined, for each speciﬁc antibiotic,
what the relative risk is of harbouring bacteria resistant to
the antibiotic after a course of the same antibiotic [10,11].
This number was used to derive the increase in risk for inap-
propriate empirical antibiotic treatment for the subsequent
infection (assuming that the policy of treating the same infec-
tions with the same antibiotic would not change in a month).
This translates into a loss of QALYs and an increase in hos-
pital days.
To calculate costs of resistance to future patients, we had
to make a number of assumptions. The main cost of resis-
tance in our model is harm to future patients because of
inappropriate empirical treatment, assuming that there is a
lag between change in resistance and change in antibiotic pol-
icy. In a full representation, we would have to model the
costs of transition to broader-spectrum antibiotics and ﬁnally
the costs of mortality and morbidity caused by pathogens
that are resistant to all useful antibiotics. Some of these data
are available [12].
We assumed that treating a patient with an antibiotic
drug means that all patients with similar infections will be
treated with the same antibiotics as a matter of policy.
Assuming that the change in antibiotic policy will take a
year or more, we can translate the antibiotic decision made
for one patient into the increase in antibiotic consumption
for this drug in the following year. This is the most difﬁcult
part: translating the increase in use into a rise in resistance,
for this speciﬁc antibiotic and for antibiotics with cross-
resistance with this one. We can assume that this relation-
ship changes with different baseline resistance levels, and
thus is different in different hospitals. Perusing the litera-
ture, we lacked both a robust model with which to
perform the calculations, and the necessary data. For the
TREAT model, we have assumed an S-shaped curve relating
consumption to rise in resistance, translating into three
almost linear parts and two ‘bends’. For each participating
hospital, we drew the resistance/consumption relationship,
making an assumption as to the location of the particular
antibiotic–hospital combination on the S-shaped curve. This
allowed us to calculate the number of patients who will be
given inappropriate empirical therapy, assuming that the
policy does not change within a year, and translate it into
number of life-years lost.
A full model will probably return some different numbers,
but ultimately these numbers will be dominated by the slope
of rise in resistance, and the life lost because of inappropri-
ate antibiotic treatment caused by this. A crucial translation
factor is missing here. What is the weight that we are assign-
ing to a life-year of a future patient against the value of a
life-year of the present patient? In a quantitative model, this
weight will have to be given a number: is it a 1 : 1 relation-
ship, or are life-years of future patients less valuable than
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those of present patients? As physicians, we are taught that
our main duty is to the present patient. In the TREAT
model, looking from the point of view of the institution and
using a relatively short time horizon, the ratio was 1. This is
not necessarily the case.
Summary
In the TREAT project, we needed an explicit model to bal-
ance between the beneﬁts and costs of antibiotic treatments
(including ‘no treatment’ and combinations of drugs). We
tried to include all of the important components, simplifying
the relationships in places in which a full model was not
available. In addition to the cost components listed above,
we used a ‘penalty factor’ that will allow policy-makers to
incorporate local preferences into the model.
The model worked well for decision support. Its analysis
showed, yet again, that, for moderate to severe infections, a
model that does not include costs of resistance to future
patients will always return maximum antibiotic treatment.
Two major moral decisions are hidden in the model: how to
take into account the limited life-expectancy and limited
quality of life of old or very sick patients; and how to assign
a value for a life-year of a future, unnamed patient vs. the
present, individual patient.
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